TRCT
AQST icon

Tower Research Capital (TRC)’s Aquestive Therapeutics AQST Stock Holding History

Tower Research Capital (TRC)’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.2K Buy
8,491
+2,481
+41% +$10.1K ﹤0.01% 3043
2025
Q4 		$38.8K Buy
6,010
+1,339
+29% +$8.34K ﹤0.01% 2620
2025
Q3 		$26.1K Sell
4,671
-1,345
-22% -$5.82K ﹤0.01% 3067
2025
Q2 		$19.9K Buy
6,016
+3,101
+106% +$8.89K ﹤0.01% 3682
2025
Q1 		$8.45K Sell
2,915
-1,024
-26% -$3.1K ﹤0.01% 3890
2024
Q4 		$14K Sell
3,939
-5,711
-59% -$26.3K ﹤0.01% 3484
2024
Q3 		$48.1K Buy
9,650
+7,050
+271% +$27.4K ﹤0.01% 2741
2024
Q2 		$6.76K Sell
2,600
-26,593
-91% -$88.8K ﹤0.01% 4543
2024
Q1 		$124K Buy
29,193
+24,837
+570% +$82.7K ﹤0.01% 1711
2023
Q4 		$8.8K Sell
4,356
-6,517
-60% -$11.5K ﹤0.01% 4462
2023
Q3 		$16.6K Sell
10,873
-3,889
-26% -$6.69K ﹤0.01% 3540
2023
Q2 		$24.4K Buy
14,762
+5,480
+59% +$9.91K ﹤0.01% 3206
2023
Q1 		$11K Buy
9,282
+4,287
+86% +$3.71K ﹤0.01% 4178
2022
Q4 		$5K Sell
4,995
-29,880
-86% -$28.1K ﹤0.01% 4828
2022
Q3 		$41K Sell
34,875
-3,264
-9% -$3.69K ﹤0.01% 3334
2022
Q2 		$24K Buy
38,139
+13,112
+52% +$17.4K ﹤0.01% 3589
2022
Q1 		$65K Buy
25,027
+23,239
+1,300% +$67.9K ﹤0.01% 2516
2021
Q4 		$7K Buy
+1,788
New +$8.97K ﹤0.01% 4887
2021
Q2 		– Sell
-12,044
Closed -$62K – 5446
2021
Q1 		$62K Buy
12,044
+7,547
+168% +$40.1K ﹤0.01% 2938
2020
Q4 		$24K Sell
4,497
-14,424
-76% -$86.4K ﹤0.01% 3742
2020
Q3 		$92K Buy
18,921
+17,938
+1,825% +$117K ﹤0.01% 3202
2020
Q2 		$5K Sell
983
-20,639
-95% -$95K ﹤0.01% 4258
2020
Q1 		$47K Buy
21,622
+8,172
+61% +$31.1K ﹤0.01% 1314
2019
Q4 		$78K Sell
13,450
-16,086
-54% -$83.7K 0.01% 1084
2019
Q3 		$94K Buy
+29,536
New +$111K 0.01% 1383
2019
Q2 		– Sell
-951
Closed -$7K – 3629
2019
Q1 		$7K Sell
951
-228
-19% -$1.6K ﹤0.01% 2849
2018
Q4 		$7K Buy
+1,179
New +$14.9K ﹤0.01% 2666

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Tower Research Capital (TRC)'s AQST Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Aquestive Therapeutics (AQST) stake by 41% in Q1 2026, buying an estimated $10.1K and bringing the position to 8,491 shares worth $35.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3043.

Tower Research Capital (TRC) first reported a position in AQST in Q4 2018 and has held it in 27 quarters since. The position peaked at $124K in Q1 2024. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Tower Research Capital (TRC) held 8,491 shares of Aquestive Therapeutics worth $35.2K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,481 Aquestive Therapeutics shares in Q1 2026, an estimated $10.1K.
  • Aquestive Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3043 holding.
  • Tower Research Capital (TRC) first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 27 quarters since.
  • Tower Research Capital (TRC)'s Aquestive Therapeutics position peaked at $124K in Q1 2024.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.